nach oben

Erschienen in:

01.03.2013 | Original Paper

CD147, MMP9 expression and clinical significance of basal-like breast cancer

Erschienen in: Medical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Our objective is to investigate the expression of CD147 and metallo-proteinase 9 (MMP9) in patients with basal-like breast cancer (BLBC) so as to determine whether these two genes may be correlated with prognosis of BLBC. We examined the expression of the CD147 and MMP9 in BLBC by immunohistochemistry. Furthermore, we analyzed the correlation between BLBC and several factors related to tumor progression, along with the prognostic value of BLBC. BLBC was significantly associated with CD147 and MMP9 expression (P = 0.000), and prone to lymph node metastasis and distant metastasis. Patients with BLBC showed shorter disease-free survival (P = 0.005) and overall survival (OS) (P = 0.011). In univariate analysis, CD147, MMP9, lymph node metastasis and clinical stage are independent prognostic factors affecting OS. In multivariate analysis, only clinical stage was identified as an independent prognostic factor. Patients with BLBC have a high expression of CD147 and MMP9; BLBC is correlated with a poor prognosis.

Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–74.PubMedCrossRef

Cleator S, Heller W, Coombers RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007;8:235–44.PubMedCrossRef

Prati R, Apple SK, Gornbein JA, Chang HR. Histopathologic characteristics predicting HER2/neu amplification in breast cancer. Breast J. 2005;11:433–9.PubMedCrossRef

Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Modern Pathol. 2008;21:S8–15.CrossRef

Billar JA, Dueck AC, Stucky CC, et al. Triple-negative breast cancers: unique clinical presentations and outcomes. Ann Surg Oncol. 2010;17 Suppl 3:384–90.

Sasa M, Bando Y, Takahashi M, Hirose T, Nagao T. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer. J Surg Oncol. 2008;97:30–4.PubMedCrossRef

Ramos-DeSimone N, Hahn-Dantona E, Sipley J, et al. Activation of matrix metalloprotease-9 (MMP9) via a converting Plasmin/Stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem. 1999;274:13066–76.PubMedCrossRef

Davidson B, Goldberg I, Berner A, et al. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis. 2003;20:161–9.PubMedCrossRef

Guo H, Li R, Zucker S, et al. EMMPRIN (CD147), an inducer of matrix metalloproteinase synthesis, also binds interstitial collagenase to the tumor cell surface. Cancer Res. 2000;60:888–91.PubMed

10.

Piao S, Zhao S, Guo F, et al. Increased expression of CD147 and MMP9 is correlated with poor prognosis of salivary duct carcinoma. J Cancer Res Clin Oncol. 2012;138(4):627–35.PubMedCrossRef

11.

Yu W, Liu J, Xiong X, et al. Expression of MMP9 and CD147 in invasive squamous cell carcinoma of the uterine cervix and their implication. Pathol Res Pract. 2009;205(10):709–15.PubMedCrossRef

12.

Li Z, Ren Y, Wu QC, et al. Macrophage migration inhibitory factor enhances neoplastic cell invasion by inducing the expression of matrix metalloproteinase 9 and interleukin-8 in nasopharyngeal carcinoma cell lines. Chin Med J. 2004;117(1):107–14.PubMed

13.

Tang J, Zhou HW, Jiang JL, Yang XM, et al. Sig-h3 is involved in the HAb18G/CD147-mediated metastasis process in human hepatoma cells. Exp Biol Med. 2007;232:344–52.

14.

Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161–74.PubMedCrossRef

15.

Mira E, Lacalle RA, Buesa JM, et al. Secreted MMP9 promotes angiogenesis more efficiently than constitutive active MMP9 bound to the tumor cell surface. J Cell Sci. 2004;117:1847–57.PubMedCrossRef

16.

Toole BP. Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function. Curr Top Dev Biol. 2003;54:371–89.PubMedCrossRef

17.

Biswas C, Zhang Y, DeCastro R, et al. The human tumor cell-derived collagenase stimulatory factor (re-named EMMPRIN) is a member of the immunoglobulin super family. Cancer Res. 1995;55:434–9.PubMed

18.

Zucker S, Hymowitz M, Rollo EE, et al. Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am J Pathol. 2001;158:1921–8.PubMedCrossRef

19.

Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109:25–32.PubMedCrossRef

20.

Tischkowitz M, Brunet JS, Begin LR, et al. Use of immunohistochemical markers can refine prognosis in TNBC. BMC Cancer. 2007;7:134.PubMedCrossRef

21.

Bidard FC, Conforti R, Boulet T, et al. Negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 ‘triple-negative’ breast cancers. Ann Oncol. 2007;18:1285–6.PubMedCrossRef

22.

Tan DS, Marchio C, Jones RL, et al. TNBC: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat. 2008;111:27–44.PubMedCrossRef

23.

Sasa M, Bando Y, Takahashi M, et al. Screening for basal marker expression is necessary for decision of therapeutic strategy for triple-negative breast cancer. J Surg Oncol. 2008;97:30–4.PubMedCrossRef

24.

Cheang MC, Voduc D, Bajdik C, et al. BLBC defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368–76.PubMedCrossRef

Titel: CD147, MMP9 expression and clinical significance of basal-like breast cancer
Publikationsdatum: 01.03.2013
Erschienen in: Medical Oncology / Ausgabe 1/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-012-0366-x

Springer Medizin

CD147, MMP9 expression and clinical significance of basal-like breast cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

Prognostic factors and clinical outcome of patients with Ewing’s sarcoma family of tumors in adults: multicentric study of the Anatolian Society of Medical Oncology

Impact of the first tumor response at eight weeks on overall survival in metastatic breast cancer patients treated with first-line combination chemotherapy

Aberrant expression of miR-199a-3p and its clinical significance in colorectal cancers

Increased expression of discoidin domain receptor 2 (DDR2): a novel independent prognostic marker of worse outcome in breast cancer patients

Decreased expression of light chain 3 (LC3) increased the risk of distant metastasis in triple-negative breast cancer

Association analyses of osteoprotegerin gene polymorphisms with bone mineral density in Chinese postmenopausal women

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie